Compare ADMA Biologics Inc (ADMA) vs Krispy Kreme Inc (DNUT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Krispy Kreme Inc — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Krispy Kreme Inc trades at $3.48 (market cap $572.37M). The key difference: ADMA Biologics Inc is far larger — about 3.7× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays a 3.47% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | DNUT | |
|---|---|---|
Market Cap | $2.13B | $572.37M |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $4.70 |
52-Week Low | $7.60 | $2.92 |
Enterprise Value | $2.20B | $1.77B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Krispy Kreme (DNUT) trades at $3.32, down 5.41% today, with a bearish technical signal and neutral oscillators. The company reported Q1 2026 EPS of -$0.05, missing expectations, though Q4 2025 and Q3 2025 beat estimates. Revenue for 2025 was $1.52B with a net loss of -$515.77M, reflecting a -33.36% net margin. Analyst consensus is 50% buy, 35.71% hold, and 14.29% sell. Recent news highlights automation efforts and new product launches to attract younger consumers.
The outlook remains challenging with persistent losses and high debt, but strategic pivots to capital-light models and international growth offer potential. Risks include execution missteps and competitive pressures. Investors should weigh turnaround progress against financial instability, with Q2 2026 earnings on August 6, 2026, as a key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →
